에어로졸 요법 시장 : 현황 분석과 예측(2023-2030년)

Aerosol Treatment - Aerosol is a system in which colloid ally present small solid or liquid particles are suspended in another gas. Medication is given out using aerosol in the form of mist droplets. Following inhalation, medication droplets travel from the mouth through the bronchi and alveoli. Aerosol therapy is one of the most efficient ways to treat respiratory problems because it distributes medication directly into the lower airways.

Aerosol therapy is used to treat a variety of causes, including chronic respiratory disorders like pneumonia and chronic obstructive pulmonary disease (COPD) and asthma. In accordance with the Centers for Disease Control and Prevention (CDC). Globally, the increasing prevalence of chronic respiratory conditions such as COPD, asthma, and pneumonia are expected to propel the growth of the aerosol treatment market.

Based on the product type, the market is segmented dry power inhalers, metered dose inhalers, nebulizers. The metered dose inhalers held a significant share of the market in 2022. Metered Dose Inhalers (MDIs) have long been a staple in the field of respiratory medicine, offering a convenient and effective way to deliver medication directly into the lungs. Several driving factors contribute to the continued popularity and widespread use of MDIs. Firstly, their compact and portable nature makes them incredibly convenient for patients who require frequent or on-the-go inhalations. This mobility allows individuals to maintain their medication routine regardless of their location, promoting better adherence to treatment plans. Secondly, MDIs offer precise and consistent dosing, ensuring that patients receive the prescribed amount of medication with each inhalation. This accuracy is vital in managing respiratory conditions and achieving optimal therapeutic outcomes.

Based on distribution channel, the market is divided into hospital pharmacies, retail pharmacies, clinics, and others. The Retail Pharmacies segment accounted for the largest revenue share in 2022 and is also anticipated to continue its dominance during the forecast period. Retail pharmacies are driven by several factors that contribute to their success and growth in the market. Firstly, the increasing demand for healthcare services and medications is a significant driving force. As the population continues to grow and age, the need for accessible and convenient sources of prescription drugs and over-the-counter medications rises. Retail pharmacies fulfill this need by providing a wide range of medicines and healthcare products, making it easy for individuals to access essential medications close to their homes or workplaces.

The global aerosol treatment market is divided into 5 primary geographic regions based on geography: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Due to the high prevalence of chronic respiratory diseases, North America is anticipated to be the most lucrative aerosol therapy market. Due to greater adoption rates, Europe is anticipated to be the second-most lucrative aerosol treatment market.

Because of its burgeoning economies, including China and India, which have large populations and rising rates of respiratory illnesses, Asia Pacific is a growing market for aerosol treatment. Due to the low adoption of aerosols for the treatment of respiratory disorders, Latin America and MEA are the aerosol treatment markets with the lowest profitability.

Some of the major players operating in the market include Cipla, Teva, Vidal Vademecum Spain, Arab Drug Company, Socopharm Laboratory, Takeda, Covis Pharma, Hycomed, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd. The market is diversified with a large number of global and regional market players.

TABLE OF CONTENTS

1. MARKET INTRODUCTION

• 1.1.Market Definitions
• 1.2.Main Objective
• 1.3.Stakeholders
• 1.4.Limitation

2. RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1.Research Process of the Aerosol Treatment MARKET
• 2.2.Research Methodology of the Aerosol Treatment MARKET
• 2.3.Respondent Profile

3. MARKET SYNOPSIS

4. EXECUTIVE SUMMARY

5. IMPACT OF COVID-19 ON THE Aerosol Treatment MARKET

6. Aerosol Treatment MARKET REVENUE (USD BN), 2020-2028F

7. MARKET INSIGHTS BY PRODUCT TYPE

• 7.1.Metered Dose Inhalers (MDIs)
• 7.2.Dry Powder Inhalers (DPIs)
• 7.3.Nebulizers

8. MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 8.1.Hospital Pharmacies
• 8.2.Retail Pharmacies
• 8.3.Clinics
• 8.4.Others

9. MARKET INSIGHTS BY REGION

• 9.1.North America
  • 9.1.1.U.S.
  • 9.1.2.Canada
  • 9.1.3.Rest of North America
• 9.2.Europe
  • 9.2.1.Germany
  • 9.2.2.U.K.
  • 9.2.3.France
  • 9.2.4.Italy
  • 9.2.5.Spain
  • 9.2.6.Rest of Europe
• 9.3.Asia-Pacific
  • 9.3.1.China
  • 9.3.2.Japan
  • 9.3.3.India
  • 9.3.4.Australia
  • 9.3.5.Rest of Asia-Pacific
• 9.4.Rest of World

10. AEROSOL TREATMENT MARKET DYNAMICS

• 10.1.Market Drivers
• 10.2.Market Challenges
• 10.3.Impact Analysis

11. AEROSOL TREATMENT MARKET OPPORTUNITIES

12. AEROSOL TREATMENT MARKET TRENDS

13. DEMAND AND SUPPLY-SIDE ANALYSIS

• 13.1.Demand Side Analysis
• 13.2.Supply Side Analysis

14. VALUE CHAIN ANALYSIS

15. COMPETITIVE SCENARIO

• 15.1.Competitive Landscape
  • 15.1.1.Porters Fiver Forces Analysis

16. COMPANY PROFILED

• 16.1.Cipla Inc.
• 16.2.Teva Pharmaceutical Industries Ltd.
• 16.3.Vidal Vademecum Spain
• 16.4.Arab Drug Company
• 16.5.Socopharm Pharmaceuticals S.A.E
• 16.6.Takeda Pharmaceutical Company Limited
• 16.7.Covis Pharma GmbH
• 16.8.Hycomed
• 16.9.Sun Pharmaceutical Industries Ltd.
• 16.10.Aurobindo Pharma Ltd.

17. DISCLAIMER